Although programmed death‐ligand 1 (PD‐L1) expression status and tumour mutational burden (TMB) have emerged as predictive markers for immunotherapy response in several cancer types,9 their predictive value for neoadjuvant immunotherapy in bladder cancer remains to be established. This evidence concerns the gene CD274 and urinary bladder cancer.